What is BioSafe Technologies?
BioSafe Technologies, Inc. is a pioneering entity dedicated to the development and distribution of non-toxic pesticide formulations. Its core mission revolves around eradicating parasites and blood-sucking insects that pose threats to both human and animal health. Established in 2000, the company has achieved notable success with its clinically tested products, including a pesticide-free lice shampoo. This flagship product is primarily exported to Europe, where it is utilized for private labeling by major pharmaceutical corporations. BioSafe's operational strategy emphasizes forging partnerships with established international distributors to navigate diverse market regulations and ensure broad product accessibility. As a recognized woman-owned business, BioSafe has garnered accolades for its significant contributions to global exports and its innovative advancements in insect control solutions.
How much funding has BioSafe Technologies raised?
BioSafe Technologies has raised a total of $29K across 1 funding round:
Debt
$29K
Debt (2021): $29K with participation from PPP
What's next for BioSafe Technologies?
With the recent influx of substantial expansion capital, BioSafe Technologies is poised for a significant scaling of its operations. The company's strategic focus on international partnerships and private labeling suggests a trajectory aimed at broadening its global footprint and enhancing its market penetration. The Series B/C stage funding context indicates that BioSafe is likely investing in expanding its manufacturing capabilities, bolstering its research and development for new non-toxic formulations, and strengthening its distribution networks across key international markets. Continued emphasis on regulatory compliance and product efficacy will be critical as the company aims to capture a larger share of the global insect control market.
See full BioSafe Technologies company page
